1.
|
14 p, 1.5 MB |
Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial
/
Lipton, Richard B. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Blumenfeld, Andrew M. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Li, Ye (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Severt, Lawrence (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Stokes, Jonathan T. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Creutz, Lela (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gandhi, Pranav (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Dodick, David (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
The oral calcitonin gene-related peptide receptor antagonist atogepant is indicated for the preventive treatment of episodic migraine. We evaluated changes in patient-reported outcomes with atogepant in adults with migraine. [...]
2023 - 10.1212/WNL.0000000000201568
Neurology, Vol. 100 (february 2023) , p. e764-e777
|
|
2.
|
13 p, 1.9 MB |
A study of differential microRNA expression profile in migraine : the microMIG exploratory study
/
Gallardo, Víctor J.. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gómez-Galván, J. B. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Asskour, L. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Torres-Ferrús, Marta (Hospital Universitari Vall d'Hebron) ;
Alpuente, Alicia (Hospital Universitari Vall d'Hebron) ;
Caronna, Edoardo (Hospital Universitari Vall d'Hebron) ;
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Several studies have described potential microRNA (miRNA) biomarkers associated with migraine, but studies are scarcely reproducible primarily due to the heterogeneous variability of participants. Increasing evidence shows that disease-related intrinsic factors together with lifestyle (environmental factors), influence epigenetic mechanisms and in turn, diseases. [...]
2023 - 10.1186/s10194-023-01542-z
Journal of headache and pain, Vol. 24 (february 2023)
|
|
3.
|
12 p, 949.5 KB |
Document of revision and updating of medication overuse headache (MOH) Documento de revisión y actualización de la cefalea por uso excesivo de medicación (CUEM)
/
González-Oria, Carmen (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Belvís, Roberto (Institut d'Investigació Biomèdica Sant Pau) ;
Cuadrado, María Luz (Universidad Complutense de Madrid. Departamento de Medicina) ;
Díaz-Insa, Samuel (Hospital Universitari i Politècnic La Fe (València)) ;
Guerrero-Peral, Ángel Luis (Hospital Clínico Universitario de Valladolid) ;
Huerta, Mariano (Hospital de Viladecans) ;
Irimia, Pablo (Clínica Universidad de Navarra) ;
Láinez, José Miguel (Hospital Clínic Universitari (València)) ;
Latorre, Germán (Hospital Universitario de Fuenlabrada ( Madrid)) ;
Leira, Rogelio (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Oterino, Agustín (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria)) ;
Pascual Gómez, Julio (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria)) ;
Porta-Etessam, Jesús (Universidad Complutense de Madrid) ;
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron) ;
Sánchez del Río, Margarita (Clínica Universidad de Navarra) ;
Santos-Lasaosa, Sonia (Instituto de Investigación Sanitaria de Aragón) ;
Universitat Autònoma de Barcelona
Introduction: Medication overuse headache is a secondary headache in which the regular or frequent use of analgesics can increase the frequency of the episodes, causing the transition from episodic to chronic headache. [...]
2021 - 10.1016/j.nrl.2020.04.029
Neurología, Vol. 36 Núm. 3 (abril 2021) , p. 229-240
|
|
4.
|
|
5.
|
|
6.
|
12 p, 986.0 KB |
Perceived barriers to career progression in the headache field : A global web-based cross-sectional survey
/
de Boer, Irene (Leiden University Medical Center) ;
Ambrosini, Anna (IRCCS Neuromed (Itàlia)) ;
Halker Singh, Rashmi B (Mayo Clinic (Estats Units d'Amèrica)) ;
Baykan, Betül (Istanbul University) ;
Buse, Dawn C (DepAlbert Einstein College of Medicine) ;
Tassorelli, Cristina (University of Pavia) ;
Jensen, Rigmor H (University of Copenhagen) ;
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Terwindt, Gisela M (Leiden University Medical Center) ;
Universitat Autònoma de Barcelona
It is well recognized that underrepresented and minoritized groups do not have the same career opportunities. However, there are limited data on the range and specifics of potential barriers that withhold people in headache medicine and science from reaching their full potential. [...]
2022 - 10.1177/03331024221123081
Cephalalgia, Vol. 42 (september 2022) , p. 1498-1509
|
|
7.
|
10 p, 705.8 KB |
Migraine-attributed burden, impact and disability, and migraine-impacted quality of life : Expert consensus on definitions from a Delphi process
/
Steiner, Timothy J (Imperial College London) ;
Terwindt, Gisela M (Leiden University Medical Center) ;
Katsarava, Zaza (EVEX Medical Corporation (Georgia)) ;
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gantenbein, Andreas R (University Hospital Zurich (Suïssa)) ;
Roche, Sarah L (Eli Lilly and Company) ;
Dell'Agnello, Grazia (Eli Lilly Italia SpA) ;
Tassorelli, Cristina (IRCCS Mondino Foundation) ;
Universitat Autònoma de Barcelona
Migraine-attributed burden, impact, disability and migraine-impacted quality of life are important concepts in clinical management, clinical and epidemiological research, and health policy, requiring clear and agreed definitions. [...]
2022 - 10.1177/03331024221110102
Cephalalgia, Vol. 42 (july 2022) , p. 1387-1396
|
|
8.
|
12 p, 503.9 KB |
Excellent Response to OnabotulinumtoxinA : Different Definitions, Different Predictors
/
Ornello, Raffaele (University of L'Aquila) ;
Baraldi, Carlo (AOU Policlinico di Modena) ;
Ahmed, Fayyaz (Hull University Teaching Hospitals) ;
Negro, Andrea (Sapienza University) ;
Miscio, Anna Maria (Fondazione IRCCS "Casa Sollievo Della Sofferenza") ;
Santoro, Antonio (Fondazione IRCCS "Casa Sollievo Della Sofferenza") ;
Alpuente, Alicia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Russo, Antonio (University of Campania "Luigi Vanvitelli") ;
Silvestro, Marcello (University of Campania "Luigi Vanvitelli") ;
Cevoli, Sabina (IRCCS Istituto delle Scienze Neurologiche di Bologna) ;
Brunelli, Nicoletta (Campus Bio-Medico University Hospital (Itàlia)) ;
Vernieri, Fabrizio (Campus Bio-Medico University Hospital (Itàlia)) ;
Grazzi, Licia (IRCCS Foundation "Carlo Besta" Neurological Institute) ;
Pani, Luca (VeraSci (Estats Units d'Amèrica)) ;
Andreou, Anna P (Guy's and St Thomas' NHS Foundation Trust (Regne Unit)) ;
Lambru, Giorgio (Guy's and St Thomas' NHS Foundation Trust (Regne Unit)) ;
Frattale, Ilaria (Tor Vergata University) ;
Kamm, Katharina (Ludwig Maximilians University München) ;
Ruscheweyh, Ruth (Ludwig Maximilians University München) ;
Russo, Marco (Azienda USL-IRCCS di Reggio Emilia) ;
Torelli, Paola (University of Parma) ;
Filatova, Elena (Sechenov First Moscow State Medical University) ;
Latysheva, Nina (Sechenov First Moscow State Medical University) ;
Gryglas-Dworak, Anna (Headache Center Wroclaw) ;
Straburzyński, Marcin (University of Warmia and Mazury) ;
Butera, Calogera (IRCCS San Raffaele Scientific Institute (Milà, Itàlia)) ;
Colombo, Bruno (IRCCS San Raffaele Scientific Institute (Milà, Itàlia)) ;
Filippi, Massimo (IRCCS San Raffaele Scientific Institute (Milà, Itàlia)) ;
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martelletti, Paolo (Sapienza University) ;
Guerzoni, Simona (University of Modena and Reggio Emilia) ;
Sacco, Simona (University of L'Aquila) ;
Universitat Autònoma de Barcelona
The identification of patients who can benefit the most from the available preventive treatments is important in chronic migraine. We explored the rate of excellent responders to onabotulinumtoxinA in a multicenter European study and explored the predictors of such response, according to different definitions. [...]
2022 - 10.3390/ijerph191710975
International journal of environmental research and public health, Vol. 19 (september 2022)
|
|
9.
|
|
10.
|
8 p, 761.9 KB |
MAB-MIG : registry of the spanish neurological society of erenumab for migraine prevention
/
Belvís, Roberto (Institut d'Investigació Biomèdica Sant Pau) ;
Irimia, Pablo (Clínica Universidad de Navarra) ;
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
González-Oria, Carmen (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Cano, Antonio (Hospital de Mataró. Consorci Sanitari del Maresme) ;
Viguera, Javier (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Sánchez, Belén (Hospital Quirónsalud Zaragoza) ;
Molina, Francisco (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Beltrán, Isabel (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Oterino, Agustín (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Cuadrado-Godia, Elisa (Hospital del Mar (Barcelona, Catalunya)) ;
Gómez-Camello, Angel (Hospital Universitario San Cecilio (Granada)) ;
Alberte-Woodward, Miguel (Hospital Universitario Lucus Augusti (Lugo)) ;
Jurado, Carmen (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Oms, Teresa (Hospital Dos de Maig) ;
Ezpeleta, David (Hospital Quironsalud Madrid) ;
de Terán, Javier Díaz (Hospital Universitario La Paz (Madrid)) ;
Morollón Sánchez-Mateos, Noemí (Hospital Universitari Dexeus (Barcelona, Catalunya)) ;
Latorre, Germán (Hospital Universitario de Fuenlabrada ( Madrid)) ;
Torres-Ferrús, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Alpuente, Alicia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Lamas, Raquel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Toledano, Carlos (Clínica Universidad de Navarra) ;
Leira, Rogelio (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Santos, Sonia (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Del Rio, Margarita Sanchez (Clínica Universidad de Navarra) ;
Universitat Autònoma de Barcelona
Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official reimbursement. [...]
2021 - 10.1186/s10194-021-01267-x
Journal of headache and pain, Vol. 22 (july 2021)
|
|